Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
TV & Film
Sports
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/f1/b9/ab/f1b9abe2-cfe0-a121-a86e-a9e051e550b8/mza_3957851291692824620.png/600x600bb.jpg
The Fellow on Call: The Heme/Onc Podcast
Rouleaux University Medical Center
147 episodes
1 week ago
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
RSS
All content for The Fellow on Call: The Heme/Onc Podcast is the property of Rouleaux University Medical Center and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1741140517043-GZJYBXJAOVDBEDRWE7NW/Ep+130.jpg?format=1500w
Episode 130: Testicular Cancer Series, Pt 4 - Role of Radiation Oncology
The Fellow on Call: The Heme/Onc Podcast
8 months ago
Episode 130: Testicular Cancer Series, Pt 4 - Role of Radiation Oncology
This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective. Episode contents: - What are important studies to send to radiation oncology prior to their appointment? - How radiation is planned for seminoma patients and a discussion of the treatment course - Implications on spermatogenesis, organ function, and infertility - Role of proton therapy? - Emerging therapies ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
The Fellow on Call: The Heme/Onc Podcast
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast